GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Panacea Acquisition Corp II (NAS:PANA) » Definitions » Cash Flow from Financing

Panacea Acquisition II (Panacea Acquisition II) Cash Flow from Financing : $0.00 Mil (TTM As of Dec. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Panacea Acquisition II Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Dec. 2022, Panacea Acquisition II paid $0.00 Mil more to buy back shares than it received from issuing new shares. It received $0.00 Mil from issuing more debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It received $0.00 Mil on other financial activities. In all, Panacea Acquisition II spent $0.00 Mil on financial activities for the three months ended in Dec. 2022.


Panacea Acquisition II Cash Flow from Financing Historical Data

The historical data trend for Panacea Acquisition II's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Panacea Acquisition II Cash Flow from Financing Chart

Panacea Acquisition II Annual Data
Trend Dec21 Dec22
Cash Flow from Financing
- -

Panacea Acquisition II Quarterly Data
Jan21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Cash Flow from Financing Get a 7-Day Free Trial - - - - -

Panacea Acquisition II Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Panacea Acquisition II's Cash from Financing for the fiscal year that ended in Dec. 2022 is calculated as:

Panacea Acquisition II's Cash from Financing for the quarter that ended in Dec. 2022 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Panacea Acquisition II  (NAS:PANA) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Panacea Acquisition II's issuance of stock for the three months ended in Dec. 2022 was $0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Panacea Acquisition II's repurchase of stock for the three months ended in Dec. 2022 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Panacea Acquisition II's net issuance of debt for the three months ended in Dec. 2022 was $0.00 Mil. Panacea Acquisition II received $0.00 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Panacea Acquisition II's net issuance of preferred for the three months ended in Dec. 2022 was $0.00 Mil. Panacea Acquisition II paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Panacea Acquisition II's cash flow for dividends for the three months ended in Dec. 2022 was $0.00 Mil. Panacea Acquisition II received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Panacea Acquisition II's other financing for the three months ended in Dec. 2022 was $0.00 Mil. Panacea Acquisition II received $0.00 Mil on other financial activities.


Panacea Acquisition II Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Panacea Acquisition II's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Panacea Acquisition II (Panacea Acquisition II) Business Description

Traded in Other Exchanges
N/A
Address
357 Tehama Street, Floor 3, San Francisco, CA, USA, 94103
Website
Panacea Acquisition Corp II is a blank check company. It is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
Executives
Ecor1 Capital Fund Qualified, L.p. director, 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ecor1 Capital, Llc director, 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Oleg Nodelman director, 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ecor1 Capital Fund, L.p. director, 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ecor1 Venture Opportunity Fund, Lp director, 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Biotech Opportunity Gp, Llc director, 10 percent owner 1370 TRANCAS STREET, SUITE 176, NAPA CA 94558
Ecor1 Panacea Holdings Ii, Llc director, 10 percent owner 357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO CA 94103
Douglas E Williams director C/O AMGEN INC, ONE AMGEN CENTER DR, THOUSAND OAKS CA 91320-1799
Douglas E. Giordano director C/O PFIZER INC., 235 EAST 42ND STREET, NEW YORK NY 10017
Nina S Kjellson director C/O INTERWEST PARTNERS, 2710 SAND HILL ROAD, SUITE 200, MENLO PARK CA 94025
Praveen P. Tipirneni director C/O MORPHIC HOLDING, INC.,, 35 GATEHOUSE DRIVE, A2, WALTHAM MA 02451
Sarah Marriott director, officer: Secretary C/O ECOR1 CAPITAL, 357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO CA 94103
Scott Perlen officer: Chief Financial Officer C/O ECOR1 CAPITAL, 357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO CA 94103
Caroline Stout officer: Chief Investment Officer C/O ECOR1 CAPITAL, 357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO CA 94103
Scott Platshon officer: Chief Operating Officer C/O ECOR1 CAPITAL, 357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO CA 94103

Panacea Acquisition II (Panacea Acquisition II) Headlines